Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms COVET
- 26 Jul 2019 Status changed from recruiting to discontinued.
- 01 Nov 2018 Planned number of patients changed from 3165 to 3000.
- 01 Nov 2018 Status changed from not yet recruiting to recruiting.